| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| P-006 | 23ME-00610; P-006; 23ME’610 | Phase 2 Clinical | 23andme Inc | Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Microsatellite instability-high cancer; Neuroendocrine Tumors; Peritoneal Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |